Immunotherapies in the treatment of immunoglobulin E‑mediated allergy: Challenges and scope for innovation (Review)

Yadav,Sarika; Singh,Saurabh; Mandal,Payal; Tripathi,Anurag

doi:10.3892/ijmm.2022.5151

Immunotherapies in the treatment of immunoglobulin E‑mediated allergy: Challenges and scope for innovation (Review)

Authors:
- Sarika Yadav
- Saurabh Singh
- Payal Mandal
- Anurag Tripathi
View Affiliations

Affiliations: Systems Toxicology and Health Risk Assessment Group, CSIR‑Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh 226001, India, Food, Drugs and Chemical Toxicology Group, CSIR‑Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh 226001, India
Published online on: May 25, 2022 https://doi.org/10.3892/ijmm.2022.5151
Article Number: 95

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunoglobulin E (IgE)‑mediated allergy or hypersensitivity reactions are generally defined as an unwanted severe symptomatic immunological reaction that occurs due to shattered or untrained peripheral tolerance of the immune system. Allergen‑specific immunotherapy (AIT) is the only therapeutic strategy that can provide a longer‑lasting symptomatic and clinical break from medications in IgE‑mediated allergy. Immunotherapies against allergic diseases comprise a successive increasing dose of allergen, which helps in developing the immune tolerance against the allergen. AITs exerttheirspecial effectiveness directly or indirectly by modulating the regulator and effector components of the immune system. The number of success stories of AIT is still limited and it canoccasionallyhave a severe treatment‑associated adverse effect on patients. Therefore, the formulation used for AIT should be appropriate and effective. The present review describes the chronological evolution of AIT, and provides a comparative account of the merits and demerits of different AITs by keeping in focus the critical guiding factors, such as sustained allergen tolerance, duration of AIT, probability of mild to severe allergic reactions and dose of allergen required to effectuate an effective AIT. The mechanisms by which regulatory T cells suppress allergen‑specific effector T cells and how loss of natural tolerance against innocuous proteins induces allergy are reviewed. The present review highlights the major AIT bottlenecks and the importantregulatory requirements for standardized AIT formulations. Furthermore, the present reviewcalls attention to the problem of ‘polyallergy’, which is still a major challenge for AIT and the emerging concept of ‘component‑resolved diagnosis’ (CRD) to address the issue. Finally, a prospective strategy for upgrading CRD to the next dimension is provided, and a potential technology for delivering thoroughly standardized AIT with minimal risk is discussed.

View Figures

View References

1	Zhang P and Lu Q: Genetic and epigenetic influences on the loss of tolerance in autoimmunity. Cell Mol Immunol. 15:575–585. 2018. View Article : Google Scholar
2	Tulic MK, Hodder M, Forsberg A, McCarthy S, Richman T, D'Vaz N, van den Biggelaar AH, Thornton CA and Prescott SL: Differences in innate immune function between allergic and nonallergic children: New insights into immune ontogeny. J Allergy Clin Immunol. 127:470–478.e1. 2011. View Article : Google Scholar
3	Rajan TV: The Gell-Coombs classification of hypersensitivity reactions: A re-interpretation. Trends Immunol. 24:376–379. 2003. View Article : Google Scholar
4	Passali D, Cingi C, Staffa P, Passali F, Muluk NB and Bellussi ML: The International study of the allergic rhinitis survey: Outcomes from 4 geographical regions. Asia Pac Allergy. 8:e72018. View Article : Google Scholar : PubMed/NCBI
5	Meltzer EO: Allergic rhinitis: Burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am. 36:235–248. 2016. View Article : Google Scholar : PubMed/NCBI
6	Pritchard DI, Falcone FH and Mitchell PD: The evolution of IgE-mediated type I hypersensitivity and its immunological value. Allergy. 76:1024–1040. 2021. View Article : Google Scholar : PubMed/NCBI
7	Cooke RA, Barnard JH, Hebald S and Stull A: Serological evidence of immunity with coexisting sensitization in a type of human allergy (Hay Fever). J Exp Med. 62:733–750. 1935. View Article : Google Scholar : PubMed/NCBI
8	Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoef A, Maillère B, Kay AB and Larché M: Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 127:89–97, 97.e1-14. 2011. View Article : Google Scholar
9	Bonini S: Regulatory aspects of allergen-specific immunotherapy: Europe sets the scene for a global approach. World Allergy Organ J. 5:120–123. 2012. View Article : Google Scholar : PubMed/NCBI
10	Gaur SN: Guidelines for allergen immunotherapy in India: 2017-An update. Indian J Allergy Asthma Immunol. 31:1–2. 2017. View Article : Google Scholar
11	Von Baehr V, Hermes A, Von Baehr R, Scherf HP, Volk HD, Fischer von Weikersthal-Drachenberg KJ and Woroniecki S: Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine. J Investig Allergol Clin Immunol. 15:234–241. 2005.
12	Hochfelder JL and Ponda P: Allergen immunotherapy: Routes, safety, efficacy, and mode of action. Immunotargets Ther. 2:61–71. 2013.PubMed/NCBI
13	Chaoul N, Albanesi M, Giliberti L, Rossi MP, Nettis E, Di Bona D, Caiaffa MF and Macchia L: Maintenance-phase subcutaneous immunotherapy with house dust mites induces cyclic immunologic effects. Int Arch Allergy Immunol. 179:37–42. 2019. View Article : Google Scholar
14	Choi JS, Ryu HR, Yoon CH, Kim JH, Baek JO, Roh JY and Lee JR: Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy. Ann Dermatol. 27:82–86. 2015. View Article : Google Scholar
15	Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, et al: Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 127 (1 Suppl):S1–S55. 2011. View Article : Google Scholar
16	Feuille E and Nowak-Wegrzyn A: Allergen-specific immunotherapies for food allergy. Allergy Asthma Immunol Res. 10:189–206. 2018. View Article : Google Scholar : PubMed/NCBI
17	Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, et al: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 62:943–948. 2007. View Article : Google Scholar : PubMed/NCBI
18	Pajno GB, Barberio G, De Luca F, Morabito L and Parmiani S: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 31:1392–1397. 2001. View Article : Google Scholar : PubMed/NCBI
19	No authors listed. The specific treatment of hay fever. JAMA. 41:1081903.
20	Noon L: Prophylactic inoculation against hay fever. Lancet. 177:1572–1573. 1911. View Article : Google Scholar
21	Black JH: The oral administration of pollen: A clinical report. J Lab Clin Med. 13:709–713. 1928.
22	Mackenzie GM and Baldwin LB: Local desensitization in hypersensitive individuals and its bearing on the prevention of hay-fever. Arch Intern Med (Chic). 28:722–732. 1921. View Article : Google Scholar
23	Scadding GK and Brostoff J: Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 16:483–491. 1986. View Article : Google Scholar : PubMed/NCBI
24	Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wüthrich B, Crameri R, Graf N, et al: Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proc Natl Acad Sci USA. 105:17908–17912. 2008. View Article : Google Scholar : PubMed/NCBI
25	Stanworth DR: The discovery of IgE. Allergy. 48:67–71. 1993. View Article : Google Scholar : PubMed/NCBI
26	Lichtenstein LM, Holtzman NA and Burnett LS: A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol. 101:317–324. 1968.
27	Marsh DG, Lichtenstein LM and Campbell DH: Studies on ‘allergoids’ prepared from naturally occurring allergens: I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology. 18:705–722. 1970.PubMed/NCBI
28	Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, et al: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA. 101 (Suppl 2):S14677–S14682. 2004. View Article : Google Scholar
29	Kouser L, Kappen J, Walton RP and Shamji MH: Update on biomarkers to monitor clinical efficacy response during and post treatment in allergen immunotherapy. Curr Treat Options Allergy. 4:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
30	Bachmann MF and Kündig TM: Allergen-specific immunotherapy: Is it vaccination against toxins after all? Allergy. 72:13–23. 2017. View Article : Google Scholar : PubMed/NCBI
31	Esch RE: Allergen source materials and quality control of allergenic extracts. Methods. 13:2–13. 1997. View Article : Google Scholar : PubMed/NCBI
32	Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H and Cromwell O: Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 116:608–613. 2005. View Article : Google Scholar
33	Grier TJ: How's my dosing? A one-step, math-free guide for comparing your clinic's maintenance immunotherapy doses to current practice parameter recommendations. Ann Allergy Asthma Immunol. 108:201–205. 2012. View Article : Google Scholar
34	Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M, Wopfner N, Thalhamer J and Achatz G: Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets. 5:5–14. 2006. View Article : Google Scholar : PubMed/NCBI
35	Jaye T: Allergy immunotherapy update. Curr Allergy Clin Immunol. 32:91–94. 2019.
36	Spiric J, Reuter A and Rabin R: Mass spectrometry to complement standardization of house dust mite and other complex allergenic extracts. Clin Exp Allergy. 47:604–617. 2017. View Article : Google Scholar : PubMed/NCBI
37	Köberlein J and Mösges R: Oralair(^®): A causal treatment for grass pollen-induced allergic rhinoconjunctivitis. Immunotherapy. 5:13–21. 2013. View Article : Google Scholar
38	Dougherty JA, Wagner JD and Stanton MC: Peanut allergen powder-dnfp: A novel oral immunotherapy to mitigate peanut allergy. Ann Pharmacother. 55:344–353. 2021. View Article : Google Scholar : PubMed/NCBI
39	Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg SA, Jensen BM, Quaak S, Akkerdaas JH, Blom L, Asturias J, et al: Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy. Int Arch Allergy Immunol. 166:41–51. 2015. View Article : Google Scholar
40	Rizvi AY and Panchal AS: Timothy grass pollen allergen extract (Grastek) for allergic rhinitis. Am Fam Physician. 92:1096–1097. 2015.PubMed/NCBI
41	Cho SW, Han DH, Kim JW, Kim DY and Rhee CS: House dust mite sublingual immunotherapy in allergic rhinitis. Immunotherapy. 10:567–578. 2018. View Article : Google Scholar : PubMed/NCBI
42	Nelson HS: Ragweed allergy immunotherapy tablet MK-3641 (Ragwitek^®) for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 14:1003–1011. 2018. View Article : Google Scholar
43	Erlich D: Peanut allergen powder (Palforzia) for peanut allergy. Am Fam Physician. 105:20–21. 2022.PubMed/NCBI
44	Thompson CP, Silvers S and Shapiro MA: Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 125:311–318.e2. 2020. View Article : Google Scholar
45	Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P and Kündig TM: Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 129:128–135. 2012. View Article : Google Scholar
46	Gaur SN: Allergoid preparations for allergen immunotherapy: A brief overview. Indian J Allergy Asthma Immunol. 32:1–3. 2018. View Article : Google Scholar
47	Carnes J, Gallego MT, Moya R and Iraola V: Allergoids for allergy treatment. Recent Pat Inflamm Allergy Drug Discov. 12:110–119. 2018. View Article : Google Scholar : PubMed/NCBI
48	Focke-Tejkl M and Valenta R: Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol. 12:555–563. 2012. View Article : Google Scholar
49	Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, Pfister T, Maurer P, Bachmann MF, Graf N and Kündig TM: Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: A phase I/IIa clinical trial. Clin Exp Allergy. 39:562–570. 2009. View Article : Google Scholar : PubMed/NCBI
50	Satitsuksanoa P, Globinska A, Jansen K, van de Veen W and Akdis M: Modified allergens for immunotherapy. Curr Allergy Asthma Rep. 18:92018. View Article : Google Scholar : PubMed/NCBI
51	Akdis CA and Blaser K: Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol. 121:261–269. 2000. View Article : Google Scholar
52	Singh N, Bhatia S, Abraham R, Basu SK, George A, Bal V and Rath S: Modulation of T cell cytokine profiles and peptide-MHC complex availability in vivo by delivery to scavenger receptors via antigen maleylation. J Immunol. 160:4869–4880. 1998.
53	Bhatia S, Mukhopadhyay S, Jarman E, Hall G, George A, Basu SK, Rath S, Lamb JR and Bal V: Scavenger receptor-specific allergen delivery elicits IFN-gamma-dominated immunity and directs established TH2-dominated responses to a nonallergic phenotype. J Allergy Clin Immunol. 109:321–328. 2002. View Article : Google Scholar
54	Tighe H, Takabayashi K, Schwartz D, Marsden R, Beck L, Corbeil J, Richman DD, Eiden JJ Jr, Spiegelberg HL and Raz E: Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol. 30:1939–1947. 2000. View Article : Google Scholar
55	Takai T, Mori A, Yuuki T, Okudaira H and Okumura Y: Non-anaphylactic combination of partially deleted fragments of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Mol Immunol. 36:1055–1065. 1999. View Article : Google Scholar
56	Swoboda I, de Weerd N, Bhalla PL, Niederberger V, Sperr WR, Valent P, Kahlert H, Fiebig H, Ebner C, Spitzauer S, et al: Hypoallergenic forms of the ryegrass pollen allergen Lol p 5 as candidates for immunotherapy. Int Arch Allergy Immunol. 124:380–382. 2001. View Article : Google Scholar
57	Wu CH, Lee MF, Yang JS and Tseng CY: IgE-binding epitopes of the American cockroach Per a 1 allergen. Mol Immunol. 39:459–464. 2002. View Article : Google Scholar
58	Kücüksezer UC, Palomares O, Rückert B, Jartti T, Puhakka T, Nandy A, Gemicioğlu B, Fahrner HB, Jung A, Deniz G, et al: Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. J Allergy Clin Immunol. 131:875–885. 2013. View Article : Google Scholar
59	Li L and Boussiotis V: Control and regulation of peripheral tolerance in allergic inflammatory disease: Therapeutic consequences. Chem Immunol Allergy. 94:178–188. 2008. View Article : Google Scholar : PubMed/NCBI
60	Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe AH, Berry G, DeKruyff RH and Umetsu DT: Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. 8:1024–1032. 2002. View Article : Google Scholar : PubMed/NCBI
61	Legoux FP, Lim JB, Cauley AW, Dikiy S, Ertelt J, Mariani TJ, Sparwasser T, Way SS and Moon JJ: CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity. 43:896–908. 2015. View Article : Google Scholar : PubMed/NCBI
62	Soroosh P, Doherty TA, Duan W, Mehta AK, Choi H, Adams YF, Mikulski Z, Khorram N, Rosenthal P, Broide DH and Croft M: Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance. J Exp Med. 210:775–788. 2013. View Article : Google Scholar : PubMed/NCBI
63	Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR and Belkaid Y: Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 204:1775–1785. 2007. View Article : Google Scholar : PubMed/NCBI
64	Akdis CA and Akdis M: Advances in allergen immunotherapy: Aiming for complete tolerance to allergens. Sci Transl Med. 7:280ps2862015. View Article : Google Scholar
65	Smarr CB, Bryce PJ and Miller SD: Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol. 33:389–414. 2013. View Article : Google Scholar
66	Akkoc T, Akdis M and Akdis CA: Update in the mechanisms of allergen-specific immunotheraphy. Allergy Asthma Immunol Res. 3:11–20. 2011. View Article : Google Scholar : PubMed/NCBI
67	Larché M, Akdis CA and Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 6:761–771. 2006. View Article : Google Scholar
68	Hughes CE, Benson RA, Bedaj M and Maffia P: Antigen-presenting cells and antigen presentation in tertiary lymphoid organs. Front Immunol. 7:4812016. View Article : Google Scholar
69	Janeway Jr CA, Travers P, Walport M and Shlomchik MJ: Principles of innate and adaptive immunity. Immunobiology: The Immune System in Health and Disease. 5th edition. Garland Science; New York: pp. 13–25. 2001
70	Kappen JH, Durham SR, Veen HI and Shamji MH: Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Ther Adv Respir Dis. 11:73–86. 2017. View Article : Google Scholar : PubMed/NCBI
71	Lawrence MG, Steinke JW and Borish L: Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy. Ann Allergy Asthma Immunol. 117:138–142. 2016. View Article : Google Scholar
72	Chang K, Song JY and Lim DS: Tolerogenic dendritic cell-based immunotherapy. Oncotarget. 8:90630–90631. 2017. View Article : Google Scholar
73	Choo EH, Lee JH, Park EH, Park HE, Jung NC, Kim TH, Koh YS, Kim E, Seung KB, Park C, et al: Infarcted myocardium-primed dendritic cells improve remodeling and cardiac function after myocardial infarction by modulating the regulatory T cell and macrophage polarization. Circulation. 135:1444–1457. 2017. View Article : Google Scholar : PubMed/NCBI
74	Lee JH, Kim TH, Park HE, Lee EG, Jung NC, Song JY, Seo HG, Seung KB, Chang K and Lim DS: Myosin-primed tolerogenic dendritic cells ameliorate experimental autoimmune myocarditis. Cardiovasc Res. 101:203–210. 2014. View Article : Google Scholar : PubMed/NCBI
75	Allam JP, Würtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, Valenta R, Wenghoefer M, Appel T, Gros E, et al: Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol. 126:638–645.e1. 2010. View Article : Google Scholar
76	Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H, Betbeder D, Balazuc AM, Van Overtvelt L and Moingeon P: Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol. 122:603–609.e5. 2008. View Article : Google Scholar
77	Morianos I and Semitekolou M: Dendritic cells: Critical regulators of allergic asthma. Int J Mol Sci. 21:79302020. View Article : Google Scholar
78	Reuter S, Lemmermann NAW, Maxeiner J, Podlech J, Beckert H, Freitag K, Teschner D, Ries F, Taube C, Buhl R, et al: Coincident airway exposure to low-potency allergen and cytomegalovirus sensitizes for allergic airway disease by viral activation of migratory dendritic cells. PLoS Pathog. 15:e10075952019. View Article : Google Scholar : PubMed/NCBI
79	Zakeri A and Russo M: Dual role of Toll-like Receptors in human and experimental asthma models. Front Immunol. 9:10272018. View Article : Google Scholar
80	Manicassamy S and Pulendran B: Dendritic cell control of tolerogenic responses. Immunol Rev. 241:206–227. 2011. View Article : Google Scholar : PubMed/NCBI
81	Ray A, Khare A, Krishnamoorthy N, Qi Z and Ray P: Regulatory T cells in many flavors control asthma. Mucosal Immunol. 3:216–229. 2010. View Article : Google Scholar
82	Akdis CA and Akdis M: Mechanisms of immune tolerance to allergens: Role of IL-10 and Tregs. J Clin Invest. 124:4678–4680. 2014. View Article : Google Scholar
83	Shamji MH, Layhadi JA, Achkova D, Kouser L, Perera-Webb A, Couto-Francisco NC, Parkin RV, Matsuoka T, Scadding G, Ashton-Rickardt PG and Durham SR: Role of IL-35 in sublingual allergen immunotherapy. J Allergy Clin Immunol. 143:1131–1142.e4. 2019. View Article : Google Scholar
84	Fujita H, Soyka MB, Akdis M and Akdis CA: Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2:22012. View Article : Google Scholar : PubMed/NCBI
85	Jeannin P, Lecoanet S, Delneste Y, Gauchat JF and Bonnefoy JY: IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol. 160:3555–3561. 1998.
86	Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K and Akdis CA: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 33:1205–1214. 2003. View Article : Google Scholar
87	Quakyi IA and Ahlers JD: Assessing CD4+ helper T-lymphocyte responses by lymphoproliferation. Methods Mol Med. 72:369–383. 2002.PubMed/NCBI
88	Gorelik L, Fields PE and Flavell RA: Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol. 165:4773–4777. 2000. View Article : Google Scholar
89	Heath VL, Murphy EE, Crain C, Tomlinson MG and O'Garra A: TGF-beta1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur J Immunol. 30:2639–2649. 2000. View Article : Google Scholar
90	Nakamura T and Ushigome H: Myeloid-derived suppressor cells as a regulator of immunity in organ transplantation. Int J Mol Sci. 19:23572018. View Article : Google Scholar
91	Chekol Abebe E, Asmamaw Dejenie T, Mengie Ayele T, Dagnew Baye N, Agegnehu Teshome A and Tilahun Muche Z: The role of regulatory B cells in health and diseases: A systemic review. J Inflamm Res. 14:75–84. 2021. View Article : Google Scholar : PubMed/NCBI
92	Katz SI, Parker D and Turk JL: B-cell suppression of delayed hypersensitivity reactions. Nature. 251:550–551. 1974. View Article : Google Scholar : PubMed/NCBI
93	van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, Rückert B, Akdis CA and Akdis M: IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 131:1204–1212. 2013. View Article : Google Scholar
94	Lee KM, Stott RT, Zhao G, SooHoo J, Xiong W, Lian MM, Fitzgerald L, Shi S, Akrawi E, Lei J, et al: TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur J Immunol. 44:1728–1736. 2014. View Article : Google Scholar
95	Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C, et al: IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 507:366–370. 2014. View Article : Google Scholar : PubMed/NCBI
96	Carter NA, Rosser EC and Mauri C: IL-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of Tr1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther. 14:R322012. View Article : Google Scholar : PubMed/NCBI
97	Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P, Dusheiko G, Gill U, et al: IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 189:3925–3935. 2012. View Article : Google Scholar
98	Mauri C and Menon M: The expanding family of regulatory B cells. Int Immunol. 27:479–486. 2015. View Article : Google Scholar
99	Zaimoku Y, Patel BA, Kajigaya S, Feng X, Alemu L, Quinones Raffo D, Groarke EM and Young NS: Deficit of circulating CD19⁺ CD24^hi CD38^hi regulatory B cells in severe aplastic anaemia. Br J Haematol. 190:610–617. 2020. View Article : Google Scholar
100	Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR and Mauri C: CD19+ CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 32:129–140. 2010. View Article : Google Scholar : PubMed/NCBI
101	Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, et al: Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 124:2034–2045. 2014. View Article : Google Scholar : PubMed/NCBI
102	Kim AS, Doherty TA, Karta MR, Das S, Baum R, Rosenthal P, Beppu A, Miller M, Kurten R and Broide DH: Regulatory B cells and T follicular helper cells are reduced in allergic rhinitis. J Allergy Clin Immunol. 138:1192–1195.e5. 2016. View Article : Google Scholar
103	Luo J, Guo H, Liu Z, Peng T, Hu X, Han M, Yang X, Zhou X and Li H: Analysis of peripheral B cell subsets in patients with allergic rhinitis. Allergy Asthma Immunol Res. 10:236–243. 2018. View Article : Google Scholar : PubMed/NCBI
104	Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A and Fallon PG: Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol. 125:1114–1124.e8. 2010. View Article : Google Scholar
105	Kanagaratham C, El Ansari YS, Lewis OL and Oettgen HC: IgE and IgG antibodies as regulators of mast cell and basophil functions in food allergy. Front Immunol. 11:6030502020. View Article : Google Scholar
106	Santos AF, James LK, Bahnson HT, Shamji MH, Couto-Francisco NC, Islam S, Houghton S, Clark AT, Stephens A, Turcanu V, et al: IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol. 135:1249–1256. 2015. View Article : Google Scholar
107	James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, Jacobson MR, Kimber I, Till SJ and Durham SR: Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 127:509–516.e1-e5. 2011. View Article : Google Scholar
108	Hassan G, Kant S, Prakash V, Verma AK, Saheer S, Singh A, Singh A, Jena NN and Wani NA: Allergen immunotherapy: Basic concepts. Indian J Allergy Asthma Immunol. 27:9–18. 2013. View Article : Google Scholar
109	Aricigil M, Muluk NB, Sakarya EU, Sakalar EG, Senturk M, Reisacher WR and Cingi C: New routes of allergen immunotherapy. Am J Rhinol Allergy. 30:193–197. 2016. View Article : Google Scholar : PubMed/NCBI
110	Di Bona D, Plaia A, Leto-Barone MS, La Piana S and Di Lorenzo G: Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. J Allergy Clin Immunol. 130:1097–1107.e2. 2012. View Article : Google Scholar
111	Cox L, Calderon M and Pfaar O: Subcutaneous allergen immunotherapy for allergic disease: Examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy. 4:601–616. 2012. View Article : Google Scholar : PubMed/NCBI
112	Krishna MT and Huissoon AP: Clinical immunology review series: An approach to desensitization. Clin Exp Immunol. 163:131–146. 2011. View Article : Google Scholar
113	Bergmann KC and Ring J: History of Allergy. Vol 100. Karger Medical and Scientific Publishers; Switzerland: 2014
114	Hesse L, Brouwer U, Petersen AH, Gras R, Bosman L, Brimnes J, Oude Elberink JNG, van Oosterhout AJM and Nawijn MC: Subcutaneous immunotherapy suppresses Th2 inflammation and induces neutralizing antibodies, but sublingual immunotherapy suppresses airway hyperresponsiveness in grass pollen mouse models for allergic asthma. Clin Exp Allergy. 48:1035–1049. 2018. View Article : Google Scholar : PubMed/NCBI
115	Jacobsen L, Wahn U and Bilo MB: Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: The effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2:82012. View Article : Google Scholar : PubMed/NCBI
116	Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, Sever ML, Bahnson HT, Lawson K, Harris KM, et al: Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: The GRASS randomized clinical trial. JAMA. 317:615–625. 2017. View Article : Google Scholar : PubMed/NCBI
117	Jongkhajornpong P and Laisuan W: Successful subcutaneous allergen-specific immunotherapy in refractory atopic keratoconjunctivitis: A case report. Case Rep Ophthalmol. 8:562–567. 2017. View Article : Google Scholar
118	Aasbjerg K, Backer V, Lund G, Holm J, Nielsen NC, Holse M, Wagtmann VR and Würtzen PA: Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy. 44:417–428. 2014. View Article : Google Scholar : PubMed/NCBI
119	Schülke S: Induction of Interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Front Immunol. 9:4552018. View Article : Google Scholar
120	Bellinghausen I, König B, Böttcher I, Knop J and Saloga J: Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction. Clin Exp Allergy. 36:1546–1555. 2006. View Article : Google Scholar
121	Taylor A, Verhagen J, Blaser K, Akdis M and Akdis CA: Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells. Immunology. 117:433–442. 2006. View Article : Google Scholar : PubMed/NCBI
122	Maggi E: T-cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol. 161:10–18. 2010. View Article : Google Scholar
123	Sousa L, Martín-Sierra C, Pereira C, Loureiro G, Tavares B, Pedreiro S, Martinho A and Paiva A: Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients. Allergy Asthma Clin Immunol. 14:452018. View Article : Google Scholar
124	Lao-Araya M, Steveling E, Scadding GW, Durham SR and Shamji MH: Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol. 134:1193–1195. e42014. View Article : Google Scholar
125	Halim TY, Hwang YY, Scanlon ST, Zaghouani H, Garbi N, Fallon PG and McKenzie AN: Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nat Immunol. 17:57–64. 2016. View Article : Google Scholar
126	Ring J, Beyer K, Biedermann T, Bircher A, Duda D, Fischer J, Friedrichs F, Fuchs T, Gieler U, Jakob T, et al: Guideline for acute therapy and management of anaphylaxis: S2 Guideline of the German society for allergology and clinical immunology (DGAKI), the association of German allergologists (AeDA), the society of pediatric allergy and environmental medicine (GPA), the German academy of allergology and environmental medicine (DAAU), the German professional association of pediatricians (BVKJ), the Austrian society for allergology and immunology (ÖGAI), the Swiss society for allergy and immunology (SGAI), the German society of anaesthesiology and intensive care medicine (DGAI), the German society of pharmacology (DGP), the German society for psychosomatic medicine (DGPM), the German working group of anaphylaxis training and education (AGATE) and the patient organization German allergy and asthma association (DAAB). Allergo J Int. 23:96–112. 2014. View Article : Google Scholar
127	Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S and Masuyama K: House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 72:435–443. 2017. View Article : Google Scholar : PubMed/NCBI
128	Lim JH, Kim JY, Han DH, Lee CH, Hong SN, Wee JH, Park SK and Rhee CS: Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. PLoS One. 12:e01822952017. View Article : Google Scholar : PubMed/NCBI
129	Frati F, Scurati S, Puccinelli P, David M, Hilaire C, Capecce M, Marcucci F and Incorvaia C: Development of a sublingual allergy vaccine for grass pollinosis. Drug Des Devel Ther. 4:99–105. 2010.PubMed/NCBI
130	Calderon MA, Penagos M, Sheikh A, Canonica GW and Durham SR: Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 41:1263–1272. 2011. View Article : Google Scholar : PubMed/NCBI
131	Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J and Novak N: Distribution of Langerhans cells and mast cells within the human oral mucosa: New application sites of allergens in sublingual immunotherapy? Allergy. 63:720–727. 2008. View Article : Google Scholar : PubMed/NCBI
132	Schulten V, Tripple V, Aasbjerg K, Backer V, Lund G, Würtzen PA, Sette A and Peters B: Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy. Clin Exp Allergy. 46:439–448. 2016. View Article : Google Scholar : PubMed/NCBI
133	Larche M: Immune mechanisms of sublingual immunotherapy: Are oral Langerhans cells the masters of tolerance? J Allergy Clin Immunol. 126:646–647. 2010. View Article : Google Scholar
134	Allam JP, Novak N, Fuchs C, Asen S, Bergé S, Appel T, Geiger E, Kochan JP and Bieber T: Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol. 112:141–148. 2003. View Article : Google Scholar
135	Moingeon P, Lombardi V, Baron-Bodo V and Mascarell L: Enhancing allergen-presentation platforms for sublingual immunotherapy. J Allergy Clin Immunol Pract. 5:23–31. 2017. View Article : Google Scholar
136	Francis JN, Till SJ and Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 111:1255–1261. 2003. View Article : Google Scholar
137	Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B and Ebner C: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol. 120:707–713. 2007. View Article : Google Scholar
138	Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderón M, Compalati E, Durham SR, et al: Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 7:62014. View Article : Google Scholar : PubMed/NCBI
139	Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, Marcucci F and Frati F: Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 95:254–258. 2005. View Article : Google Scholar
140	Saporta D: Sublingual immunotherapy: A useful tool for the allergist in private practice. Biomed Res Int. 2016:93238042016. View Article : Google Scholar
141	Feuille E and Nowak-Węgrzyn A: Oral immunotherapy for food allergies. Ann Nutr Metab. 68 (Suppl 1):S19–S31. 2016. View Article : Google Scholar
142	Wang YT, Liu HC, Chen HC, Lee YC, Tsai TC, Chen HL, Fan HC and Chen CM: Oral immunotherapy with the ingestion of house dust mite extract in a murine model of allergic asthma. Allergy Asthma Clin Immunol. 14:432018. View Article : Google Scholar
143	Khoriaty E and Umetsu DT: Oral immunotherapy for food allergy: Towards a new horizon. Allergy Asthma Immunol Res. 5:3–15. 2013. View Article : Google Scholar : PubMed/NCBI
144	Pandiyan P, Bhaskaran N, Zou M, Schneider E, Jayaraman S and Huehn J: Microbiome dependent regulation of T_regs and Th17 cells in Mucosa. Front Immunol. 10:4262019. View Article : Google Scholar
145	Faria AM and Weiner HL: Oral tolerance: Mechanisms and therapeutic applications. Adv Immunol. 73:153–264. 1999. View Article : Google Scholar
146	Smaldini PL, Orsini Delgado ML, Fossati CA and Docena GH: Orally-induced intestinal CD4+ CD25+ FoxP3+ Treg controlled undesired responses towards oral antigens and effectively dampened food allergic reactions. PLoS One. 10:e01411162015. View Article : Google Scholar : PubMed/NCBI
147	Mizrahi M and Ilan Y: The gut mucosa as a site for induction of regulatory T-cells. Curr Pharm Des. 15:1191–1202. 2009. View Article : Google Scholar : PubMed/NCBI
148	Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, Scurlock AM, Gimenez G, Bardina L, Sampson HA and Burks AW: Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol. 131:128–134.e1-3. 2013. View Article : Google Scholar
149	Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, et al: Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 133:468–475. 2014. View Article : Google Scholar
150	Sampson HA: Peanut oral immunotherapy: Is it ready for clinical practice? J Allergy Clin Immunol Pract. 1:15–21. 2013. View Article : Google Scholar
151	Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, Brożek JL and Schünemann HJ: Oral immunotherapy for peanut allergy (PACE): A systematic review and meta-analysis of efficacy and safety. Lancet. 393:2222–2232. 2019. View Article : Google Scholar
152	Anagnostou A: Weighing the benefits and risks of oral immunotherapy in clinical practice. Allergy Asthma Proc. 42:118–123. 2021. View Article : Google Scholar
153	Dioszeghy V, Mondoulet L, Laoubi L, Dhelft V, Plaquet C, Bouzereau A, Dupont C and Sampson H: Antigen uptake by langerhans cells is required for the induction of regulatory T cells and the acquisition of tolerance during epicutaneous immunotherapy in OVA-sensitized mice. Front Immunol. 9:19512018. View Article : Google Scholar
154	Senti G, von Moos S and Kündig TM: Epicutaneous immunotherapy for aeroallergen and food allergy. Curr Treat Options Allergy. 1:68–78. 2014. View Article : Google Scholar : PubMed/NCBI
155	Gorfu G, Rivera-Nieves J and Ley K: Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med. 9:836–850. 2009. View Article : Google Scholar : PubMed/NCBI
156	Yu LC: Intestinal epithelial barrier dysfunction in food hypersensitivity. J Allergy (Cairo). 2012:5960812012.PubMed/NCBI
157	Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA and Berin MC: Epicutaneous immunotherapy induces gastrointestinal LAP⁺ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 139:189–201.e4. 2017. View Article : Google Scholar
158	Plunkett CH and Nagler CR: The influence of the microbiome on allergic sensitization to food. J Immunol. 198:581–589. 2017. View Article : Google Scholar
159	Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C and Benhamou PH: Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 40:659–667. 2010. View Article : Google Scholar : PubMed/NCBI
160	Mondoulet L, Dioszeghy V, Puteaux E, Ligouis M, Dhelft V, Letourneur F, Dupont C and Benhamou PH: Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy. 2:222012. View Article : Google Scholar : PubMed/NCBI
161	Dupont C, Kalach N, Soulaines P, Legoué-Morillon S, Piloquet H and Benhamou PH: Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 125:1165–1167. 2010. View Article : Google Scholar
162	Senti G, Johansen P and Kundig TM: Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 9:537–543. 2009. View Article : Google Scholar
163	Hylander T, Latif L, Petersson-Westin U and Cardell LO: Intralymphatic allergen-specific immunotherapy: An effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 131:412–420. 2013. View Article : Google Scholar
164	Kim ST, Park SH, Lee SM and Lee SP: Allergen-specific intralymphatic immunotherapy in human and animal studies. Asia Pac Allergy. 7:131–137. 2017. View Article : Google Scholar : PubMed/NCBI
165	Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, Di Bona D, Pfaar O, Ahlbeck L, Akdis M, et al: Intralymphatic immunotherapy: Update and unmet needs. Int Arch Allergy Immunol. 178:141–149. 2019. View Article : Google Scholar
166	Martínez-Gómez JM, Johansen P, Erdmann I, Senti G, Crameri R and Kündig TM: Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 150:59–65. 2009. View Article : Google Scholar
167	Freiberger SN, Zehnder M, Gafvelin G, Gronlund H, Kundig TM and Johansen P: IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy. 71:1366–1370. 2016. View Article : Google Scholar : PubMed/NCBI
168	Konradsen JR, Grundström J, Hellkvist L, Tran TAT, Andersson N, Gafvelin G, Kiewiet MBG, Hamsten C, Tang J, Parkin RV, et al: Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: A randomized trial. J Allergy Clin Immunol. 145:1005–1007.e7. 2020. View Article : Google Scholar
169	Rajakulendran M, Tham EH, Soh JY and Van Bever HP: Novel strategies in immunotherapy for allergic diseases. Asia Pac Allergy. 8:e142018. View Article : Google Scholar : PubMed/NCBI
170	Fischer N, Rostaher A and Favrot C: Intralymphatic immunotherapy: An effective and safe alternative route for canine atopic dermatitis. Schweiz Arch Tierheilkd. 158:646–652. 2016.(In German). View Article : Google Scholar : PubMed/NCBI
171	Nelson MR and Cox L: Allergen immunotherapy extract preparation manual. Practice Management Resource Guide. 2014 edition. American Academy of Allergy, Asthma & Immunology; pp. 1–30. 2014
172	Nony E, Martelet A, Jain K and Moingeon P: Allergen extracts for immunotherapy: To mix or not to mix? Expert Rev Clin Pharmacol. 9:401–408. 2016. View Article : Google Scholar
173	Helyeh S, David L and Gary S: Advances in the management of food allergy in children. Curr Pediatr Rev. 14:150–155. 2018. View Article : Google Scholar : PubMed/NCBI
174	Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, Beyer K, Bindslev-Jensen C, Burks W, Ebisawa M, et al: EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 73:799–815. 2018. View Article : Google Scholar : PubMed/NCBI
175	Pfaar O, Alvaro M, Cardona V, Hamelmann E, Mosges R and Kleine-Tebbe J: Clinical trials in allergen immunotherapy: Current concepts and future needs. Allergy. 73:1775–1783. 2018. View Article : Google Scholar : PubMed/NCBI
176	Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, Friedrichs F, Fuchs T, Hamelmann E, Hartwig-Bade D, et al: Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k guideline of the German society for allergology and clinical immunology (DGAKI), the society for pediatric allergy and environmental medicine (GPA), the medical association of German allergologists (AeDA), the Austrian society for allergy and immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German society of pediatrics and adolescent medicine (DGKJ), the society for pediatric pneumology (GPP), the German respiratory society (DGP), the German association of ENT surgeons (BV-HNO), the professional federation of paediatricians and youth doctors (BVKJ), the federal association of pulmonologists (BDP) and the German dermatologists association (BVDD). Allergo J Int. 23:282–319. 2014. View Article : Google Scholar
177	Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, Ryan D, Agache I, Ansotegui IJ, Arasi S, et al: EAACI guidelines on allergen immunotherapy: prevention of allergy. Pediatr Allergy Immunol. 28:728–745. 2017. View Article : Google Scholar
178	Globinska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, van de Veen W, Sokolowska M and Akdis M: Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 121:306–312. 2018. View Article : Google Scholar
179	Chen J, Zhou Y, Wang Y, Zheng Y, Lai X, Westermann-Clark E, Cho SH and Kong W: Specific immunoglobulin E and immunoglobulin G4 toward major allergens of house-dust mite during allergen-specific immunotherapy. Am J Rhinol Allergy. 31:156–160. 2017. View Article : Google Scholar : PubMed/NCBI
180	Ciprandi G, Tosca MA and Silvestri M: The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy. Expert Rev Clin Immunol. 10:321–324. 2014. View Article : Google Scholar
181	Palomares O, Martin-Fontecha M, Lauener R, Traidl-Hoffmann C, Cavkaytar O, Akdis M and Akdis CA: Regulatory T cells and immune regulation of allergic diseases: Roles of IL-10 and TGF-beta. Genes Immun. 15:511–520. 2014. View Article : Google Scholar : PubMed/NCBI
182	Licari A, Castagnoli R, Brambilla I, Tosca MA, De Filippo M, Marseglia G and Ciprandi G: Biomarkers of immunotherapy response in patients with allergic rhinitis. Expert Rev Clin Immunol. 14:657–663. 2018. View Article : Google Scholar
183	Gueguen C, Bouley J, Moussu H, Luce S, Duchateau M, Chamot-Rooke J, Pallardy M, Lombardi V, Nony E, Baron-Bodo V, et al: Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 137:545–558. 2016. View Article : Google Scholar
184	Caruso M, Cibella F, Emma R, Campagna D, Tringali G, Amaradio MD and Polosa R: Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis. Int Immunopharmacol. 60:50–58. 2018. View Article : Google Scholar
185	Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, Azar A, Baroody FM, Bachert C, Canonica GW, et al: International consensus statement on allergy and rhinology: Allergic rhinitis. Int Forum Allergy Rhinol. 8:108–352. 2018. View Article : Google Scholar
186	Demoly P, Passalacqua G, Pfaar O, Sastre J and Wahn U: Management of the polyallergic patient with allergy immunotherapy: A practice-based approach. Allergy Asthma Clin Immunol. 12:22016. View Article : Google Scholar
187	Ciprandi G, Alesina R, Ariano R, Aurnia P, Borrelli P, Cadario G, Capristo A, Carosso A, Casino G, Castiglioni G, et al: Characteristics of patients with allergic polysensitization: The POLISMAIL study. Eur Ann Allergy Clin Immunol. 40:77–83. 2008.
188	Shamji MH and Durham SR: Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 140:1485–1498. 2017. View Article : Google Scholar
189	Daigle BJ and Rekkerth DJ: Practical recommendations for mixing allergy immunotherapy extracts. Allergy Rhinol (Providence). 6:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
190	Bahceciler NN, Galip N and Cobanoglu N: Multiallergen-specific immunotherapy in polysensitized patients: Where are we? Immunotherapy. 5:183–190. 2013. View Article : Google Scholar : PubMed/NCBI
191	Chruszcz M, Kapingidza AB, Dolamore C and Kowal K: A robust method for the estimation and visualization of IgE cross-reactivity likelihood between allergens belonging to the same protein family. PLoS One. 13:e02082762018. View Article : Google Scholar : PubMed/NCBI
192	Dodig S and Čepelak I: The potential of component-resolved diagnosis in laboratory diagnostics of allergy. Biochem Med (Zagreb). 28:0205012018. View Article : Google Scholar : PubMed/NCBI
193	Treudler R and Simon JC: Overview of component resolved diagnostics. Curr Allergy Asthma Rep. 13:110–117. 2013. View Article : Google Scholar : PubMed/NCBI
194	Ebo DG: Component-resolved allergy diagnosis: A new era? Verh K Acad Geneeskd Belg. 73:163–179. 2011.PubMed/NCBI
195	Valenta R, Campana R, Marth K and van Hage M: Allergen-specific immunotherapy: From therapeutic vaccines to prophylactic approaches. J Intern Med. 272:144–157. 2012. View Article : Google Scholar : PubMed/NCBI
196	Luengo O and Cardona V: Component resolved diagnosis: When should it be used? Clin Transl Allergy. 4:282014. View Article : Google Scholar : PubMed/NCBI
197	Alessandri C, Ferrara R, Bernardi ML, Zennaro D, Tuppo L, Giangrieco I, Tamburrini M, Mari A and Ciardiello MA: Diagnosing allergic sensitizations in the third millennium: Why clinicians should know allergen molecule structures. Clin Transl Allergy. 7:212017. View Article : Google Scholar : PubMed/NCBI
198	Marth K, Focke-Tejkl M, Lupinek C, Valenta R and Niederberger V: Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr Treat Options Allergy. 1:91–106. 2014. View Article : Google Scholar : PubMed/NCBI
199	Curin M, Garib V and Valenta R: Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment. Ann Allergy Asthma Immunol. 119:201–209. 2017. View Article : Google Scholar
200	Gaur SN: Future modalities in allergen immunotherapy: A brief overview. Indian J Allergy Asthma Immunol. 32:43–46. 2018. View Article : Google Scholar
201	Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D and Valenta R: Strategies for converting allergens into hypoallergenic vaccine candidates. Methods. 32:313–320. 2004. View Article : Google Scholar : PubMed/NCBI
202	Valenta R, Campana R, Focke-Tejkl M and Niederberger V: Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol. 137:351–357. 2016. View Article : Google Scholar
203	Larsen JN and Dreborg S: Standardization of allergen extracts. Methods Mol Med. 138:133–145. 2008. View Article : Google Scholar : PubMed/NCBI
204	Akdis CA, Blesken T, Akdis M, Wuthrich B and Blaser K: Role of interleukin 10 in specific immunotherapy. J Clin Invest. 102:98–106. 1998. View Article : Google Scholar
205	Levy BD: Resolvin D1 and Resolvin E1 promote the resolution of allergic airway inflammation via shared and distinct molecular counter-regulatory pathways. Front Immunol. 3:3902012. View Article : Google Scholar
206	Lotfi R, Rezaiemanesh A, Mortazavi SH, Karaji AG and Salari F: Immunoresolvents in asthma and allergic diseases: Review and update. J Cell Physiol. 234:8579–8596. 2019. View Article : Google Scholar
207	Kim N, Ramon S, Thatcher TH, Woeller CF, Sime PJ and Phipps RP: Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production. Eur J Immunol. 46:81–91. 2016. View Article : Google Scholar
208	Karra L, Haworth O, Priluck R, Levy BD and Levi-Schaffer F: Lipoxin B₄ promotes the resolution of allergic inflammation in the upper and lower airways of mice. Mucosal Immunol. 8:852–862. 2015. View Article : Google Scholar
209	Flesher RP, Herbert C and Kumar RK: Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma. Clin Sci (Lond). 126:805–814. 2014. View Article : Google Scholar : PubMed/NCBI
210	Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ and Serhan CN: Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol. 178:496–502. 2007. View Article : Google Scholar
211	Krishnamoorthy N, Burkett PR, Dalli J, Abdulnour RE, Colas R, Ramon S, Phipps RP, Petasis NA, Kuchroo VK, Serhan CN and Levy BD: Cutting edge: Maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation. J Immunol. 194:863–867. 2015. View Article : Google Scholar
212	Zaiss DM, Minutti CM and Knipper JA: Immune- and non-immune-mediated roles of regulatory T-cells during wound healing. Immunology. 157:190–197. 2019. View Article : Google Scholar : PubMed/NCBI
213	Di Bona D, Plaia A, Scafidi V, Leto-Barone MS and Di Lorenzo G: Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A systematic review and meta-analysis. J Allergy Clin Immunol. 126:558–566. 2010. View Article : Google Scholar
214	Harrison OJ and Powrie FM: Regulatory T cells and immune tolerance in the intestine. Cold Spring Harb Perspect Biol. 5:a0183412013. View Article : Google Scholar
215	de Chaisemartin L: Lymphocyte Homing and Trafficking. Encyclopedia of Inflammatory Diseases. Parnham M: Birkhäuser; Basel: pp. 1–8. 2013, View Article : Google Scholar
216	De Calisto J, Villablanca EJ, Wang S, Bono MR, Rosemblatt M and Mora JR: T-cell homing to the gut mucosa: General concepts and methodological considerations. Methods Mol Biol. 757:411–434. 2012. View Article : Google Scholar
217	Weinberg EG: The WAO white book on allergy 2011–2012. Curr Allergy Clin Immunol. 24:156–157. 2011.
218	Ansotegui IJ, Melioli G, Canonica GW, Caraballo L, Villa E, Ebisawa M, Passalacqua G, Savi E, Ebo D, Gómez RM, et al: IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J. 13:1000802020. View Article : Google Scholar : PubMed/NCBI
219	Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ, Rodriguez del Rio P, Tsoumani M, Gawlik R, Paraskevopoulos G, et al: Clinical contraindications to allergen immunotherapy: An EAACI position paper. Allergy. 70:897–909. 2015. View Article : Google Scholar : PubMed/NCBI
220	Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, et al: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. J Eur Acad Dermatol Venereol. 32:850–878. 2018. View Article : Google Scholar
221	Lommatzsch M: Current asthma treatment in light of new asthma guidelines. Dtsch Med Wochenschr. 143:806–810. 2018.(In German). View Article : Google Scholar : PubMed/NCBI
222	Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, et al: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. J Eur Acad Dermatol Venereol. 32:657–682. 2018. View Article : Google Scholar